Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 186 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations MOST POPULAR Young Tulsa Mom Grows Closer To Her Own Mom During Almost... May 10, 2019 Glucose Control Key in Reducing Cancer Risk for People with Type... December 7, 2021 Health inequalities: Why do people smoke if they know it’s bad... April 1, 2022 Her Mother Died of Breast Cancer When She Was Five. 16... June 25, 2019 Load more HOT NEWS With Longer Follow-Up, Trastuzumab Deruxtecan Continues to Demonstrate Superior Efficacy Over... Stopping Treatment Is a Reasonable Strategy for Patients with Advanced NSCLC... A Large Genomic Analysis Identifies That Persistent Tumour Mutational Burden Is... EMA Recommends Extending Indications for Trastuzumab Deruxtecan to Include Treatment of...
